Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis clinical trials

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 11 companies, 7 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

• 16 Apr 2027 est.resiquimod · Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3 main aim+ Cyclophosphamide, Rituximab, Azathioprine vs Prednisoneadded to Cyclophosphamideadded to RituximabNCT07168161 BDB-001 Phase III Trial in ANCA-Associated Vasculitis — primary endpoint: The proportion of patients achieving disease remission assessed by Birmingham Vasculitis Activity Score (BVAS) · 300 enrolled
• 11 Oct 2027 est.tarperprumig · AstraZeneca · Phase 2 main aimNCT07160608 Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis — primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) · 78 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.